Is Remdesivir a miracle drug for novel coronavirus? CCP has antidote

The first patient in the U.S. with Wuhan coronavirus infection got better after intravenous remdesivir treatment. China will conduct clinical trial of remdesivir.

According to Miles Guo’s live broadcast on Saturday, Feb 1, the Chinese Communist Party (CCP) will not release its “antidote” until a large-scale novel coronavirus outbreak in Hong Kong. It seems that the Wuhan coronavirus outbreak was “designed” for crippling Hong Kong. The CCP wants Hong Kong Island but not its people: 留港不留人。

The CCP was not able to crush the seven-month-long protest in Hong Kong, so it has been trying to find a legitimate excuse to impose martial law in Hong Kong to purge pro-democracy activists. A viral outbreak can be CCP’s evil plot to put Hong Kong under control.

The Chinese government does not allow Hong Kong to take effective measures to curb the spread of novel coronavirus. It is delaying a travel ban to stop mainland people from entering Hong Kong. This has angered the Hong Kong residents and prompted more protests.

Chinese government will start the clinical trial of remdesivir

Professor Lu Hongzhou, secretary of the Party Committee of Shanghai Public Health Clinical Center and expert group of the Health and Health Committee, said that at present, the expert group has written a plan and application, and reported it to the supervising department, and also contacted Gilead directly. From the research of the American counterparts, the clinical efficacy of this drug is immediate. Past records also have shown remdesivir’s outstanding performance in the field of MERS virus treatment. Once approved, relevant departments will also open green channels to introduce drugs to benefit the Chinese patients.

Remdesivir on Wikipedia

Remdesivir (development code GS-5734) is an antiviral drug, a novel nucleotide analog prodrug. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections, though it has subsequently also been found to show reasonable antiviral activity against more distantly related viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, and MERS-coronavirus. There is possible activity against other coronaviruses such as SARS, and potentially 2019-nCoV infections. It may also help protect against Nipah and Hendra virus infections.

“First Case of 2019 Novel Coronavirus in the United States”

A report published on the New England Journal of Medicine:

https://www.nejm.org/doi/full/10.1056/NEJMoa2001191?query=featured_home

0
0 Comments
Inline Feedbacks
View all comments

Popular Articles

GM35

Feb. 02, 2020